BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35585049)

  • 1. AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis.
    Kim H; Jeong M; Na DH; Ryu SH; Jeong EI; Jung K; Kang J; Lee HJ; Sim T; Yu DY; Yu HC; Cho BH; Jung YK
    Cell Death Dis; 2022 May; 13(5):469. PubMed ID: 35585049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth.
    Kim H; Lee HJ; Oh Y; Choi SG; Hong SH; Kim HJ; Lee SY; Choi JW; Su Hwang D; Kim KS; Kim HJ; Zhang J; Youn HJ; Noh DY; Jung YK
    Nat Commun; 2014; 5():3351. PubMed ID: 24548998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
    Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
    Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression.
    Śmiech M; Leszczyński P; Wardell C; Poznański P; Pierzchała M; Taniguchi H
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
    Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
    Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
    Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro.
    Böttcher K; Longato L; Marrone G; Mazza G; Ghemtio L; Hall A; Luong TV; Caruso S; Viollet B; Zucman-Rossi J; Pinzani M; Rombouts K
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G543-G556. PubMed ID: 33406006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RDIVpSGP motif of ASPP2 binds to 14-3-3 and enhances ASPP2/k18/14-3-3 ternary complex formulation to promote BRAF/MEK/ERK signal inhibited cell proliferation in hepatocellular carcinoma.
    Yang T; Zhu C; Shi Y; Shen Y; Gao Y; Zhang B; Jin R; Liu D; Ouyang Y; Liu X; Wang W; Yang P; Xu Q; Cai J; Chen D
    Cancer Gene Ther; 2022 Nov; 29(11):1616-1627. PubMed ID: 35504951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing.
    Dzeja P; Terzic A
    Int J Mol Sci; 2009 Apr; 10(4):1729-1772. PubMed ID: 19468337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
    Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
    Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
    Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
    Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.